PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of “Moderate Buy” by Brokerages

PepGen, Inc. (NASDAQ:PEPG) has been assigned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $11.50.

Several analysts recently weighed in on PEPG shares. Wall Street Zen upgraded PepGen from a “sell” rating to a “hold” rating in a report on Sunday, June 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of PepGen in a research report on Friday, August 28th. Wedbush reduced their target price on shares of PepGen from $5.00 to $4.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 13th. HC Wainwright restated a “buy” rating on shares of PepGen in a report on Wednesday. Finally, Craig Hallum initiated coverage on shares of PepGen in a report on Tuesday, June 16th. They issued a “buy” rating and a $11.00 target price for the company.

Institutional Trading of PepGen

Institutional investors have recently added to or reduced their stakes in the company. Burkehill Global Management LP purchased a new position in shares of PepGen during the third quarter valued at approximately $46,000. Jefferies Financial Group Inc. purchased a new stake in shares of PepGen in the fourth quarter worth approximately $89,000. Militia Capital Partners LP purchased a new stake in shares of PepGen in the third quarter worth approximately $72,000. Trexquant Investment LP bought a new stake in shares of PepGen during the 4th quarter worth approximately $158,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of PepGen during the 4th quarter worth approximately $180,000. Institutional investors own 58.01% of the company’s stock.

PepGen Price Performance

Shares of NASDAQ PEPG opened at $3.15 on Thursday. PepGen has a 1-year low of $1.31 and a 1-year high of $7.80. The business’s 50 day moving average is $2.54 and its two-hundred day moving average is $2.71. The stock has a market capitalization of $218.17 million, a P/E ratio of -2.40 and a beta of 1.97.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02. As a group, equities research analysts anticipate that PepGen will post -1.11 earnings per share for the current fiscal year.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).